Form 8-K · Current Report · Filed 2025-08-01
ResMed Inc. Announces Departure of Chief Commercial Officer
On July 28, 2025, Bobby Ghoshal, the Chief Commercial Officer of ResMed Inc.'s residential care software business (RCS), announced his intention to resign effective August 1, 2025.
- Filer
- ResMed Inc. RMD · NYSE
- Filed
- Accession
- 0001193125-25-170718
- CIK
- 0000943819
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
Ghoshal plans to pursue a new role as Chief Operating Officer at a software company in a non-competitive industry. The resignation was disclosed in a Form 8-K filing with the SEC.
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Market reaction
Close before filing
$271.94
Next session
+7.2%
Since filing
-22.4%
Latest close
$210.98
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RMD reporting the same item, with the next session's move:
About ResMed Inc.
ResMed Inc. is an innovative leader in the development and manufacturing of devices focused on improving the quality of sleep and respiratory health. Operating globally, ResMed specializes in producing advanced equipment for sleep apnea therapy, chronic obstructive pulmonary disease (COPD), and various respiratory conditions. The company's offerings include a range of cutting-edge products like continuous positive airway pressure (CPAP) devices, bilevel systems, and ventilators, designed to enhance patient comfort and compliance. ResMed is also at the forefront of integrating cloud-connected devices to support improved patient monitoring and telemedicine services. The healthcare industry, particularly the medical device sector, benefits significantly from ResMed's contributions, as the company aims to address the growing needs associated with sleep and respiratory conditions. By focusing on both personal and overarching health care solutions, ResMed plays a crucial role in enhancing patient quality of life, thereby solidifying its position as a key player in the global health and respiratory care markets.
Never miss another RMD filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.